BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Week in Review: Sinopharm Group Building M&A War Chest


4/1/2013 9:38:52 AM

by Richard Daverman, PhD

March 30, 2013 -- Sinopharm Group raised $515 million to fund its growth in the China drug distribution sector by selling new shares, adding to the $640 million it raised in bonds earlier this month; SK Biopharma of South Korea will collaborate with two China companies to develop its novel CNS drug; Weihai Weigao Medical Devices will distribute TriReme Medical’s portfolio of cardiovascular devices; China’s Ministry of Health issued a new essential medicine list with 520 products, up from 307 in the 2009 list; General Electric Healthcare will double production of its medical imaging devices in China; Agenix of Australia expects to file a China clinical trial application for its hepatitis B drug candidate by June; Life Technologies received SFDA approval of an Applied Biosystems sequencer while its JV with Daan Gene develops 10 diagnostic assays for use on the machine; and Cellular Biomed started a China clinical trial of a personalized treatment for liver cancer. More details….

Stock Symbols: (HK: 1099) (HK: 1066) (NYSE: GE) (ASX: AGX) (NSDQ: LIFE) (OTCQB: CBMG)



Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES